Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "kidney-diseases"

17 News Found

AIIA Goa conducts induction programme for first batch of BAMS student
News | February 23, 2023

AIIA Goa conducts induction programme for first batch of BAMS student

Ayurveda is one of the most advanced sciences of its times


AstraZeneca’s Dapagliflozin receives CDSCO approval
Drug Approval | November 30, 2022

AstraZeneca’s Dapagliflozin receives CDSCO approval

Dapagliflozin reduces the risk of sustained eGFR, cardiovascular deaths and hospitalization for heart failure in adults with CKD


PM Modi dedicates to the nation various healthcare facilities in Civil Hospital Asarwa, Ahmedabad
News | October 12, 2022

PM Modi dedicates to the nation various healthcare facilities in Civil Hospital Asarwa, Ahmedabad

Prime Minister said that it is a huge day for health in Gujarat and congratulated everyone associated with these projects for completing them on time.


AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy
News | July 27, 2022

AstraZeneca collaborates with – Indian Society of Nephrology to launch CKD Academy

AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.


Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Biotech | April 05, 2022

Good business performance gives Boehringer Ingelheim tailwind for investment in R&D

R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)


Insilico Medicine and University of Zurich partner to find therapy for Cystinosis
News | March 10, 2022

Insilico Medicine and University of Zurich partner to find therapy for Cystinosis

The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis


NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines
Policy | August 11, 2021

NPPA has put a cap on the trade margin of 42 select non-scheduled anti-cancer medicines

A total of 526 brands has seen a reduction of up to 90 per cent in MRP